020 3311 1077

Mary Clarke


Dr Hirah Rizki is a consultant breast and reconstructive surgeon specialising in the diagnosis and treatment of breast cancer. Her expertise lies in oncoplastic breast surgery and reconstruction, seamlessly integrating principles from both oncology and plastic surgery. This comprehensive approach ensures holistic care, emphasizing both cancer treatment and aesthetic outcomes. Dr Rizki has been serving as a consultant oncoplastic breast surgeon at Imperial College Healthcare NHS Trust since 2021.

Having graduated from Imperial College London in 2008 with a medical degree (MBBS) and a BSc (Hons) in Medical Sciences with Management, Dr Rizki continued to excel in her career. She successfully passed the MRCS and FRCS examinations in surgery and underwent specialized training, including a prestigious Oncoplastic TIG fellowship at the Royal Marsden Hospital. This fellowship honed her skills in advanced breast surgery and reconstruction.

Dr Rizki holds several distinguished positions, including the role of clinical governance lead for breast surgery at the Trust, where she elevates departmental standards. Additionally, her advisory position at Exact Sciences enhances her influence, providing valuable insights into the use of genetic profiling in cancer. She has contributed significantly to the field through numerous publications on breast cancer treatments in collaboration with colleagues.

Education is at the forefront of Dr Rizki's endeavours. She mentors medical students at Imperial College London, emphasizing compassionate patient care. In addition, she serves as an educational and clinical supervisor, guiding surgical trainees in West London. Furthermore, she hosts an educational podcast where she discusses recent evidence guiding best practices in breast cancer treatment.

Dr Rizki envisions a healthcare landscape characterised by personalised, efficient, and empathetic care. Her dedication to innovative practices and clinical skills in oncoplastic breast surgery and reconstruction drives her commitment to shaping the future of healthcare.


Research & publications

Abbas A, Rizki H, Tanska A, Concepcion M, Tasoulis MK, Gui G. A Comparative Study of Secondary Procedures after Subpectoral and Prepectoral Single-Stage Implant-Based Breast Reconstruction. Plast Reconstr Surg. 2023 Jan 1;151(1):7-15. doi: 10.1097/PRS.0000000000009745. Epub 2022 Oct 4. PubMed PMID: 36194056.

St John ER, Ezzat A, Holford N, Rizki H, Hogben K, Leff DR. Digital consent to improve patient perception of shared decision-making: comparative study between paper and digital consent processes in patients undergoing breast surgery. Br J Surg. 2022 Oct 14;109(11):1172-1173. doi: 10.1093/bjs/znac285. PubMed PMID: 35960998.

Hillyar CR, Rizki H, Begum R, Gupta A, Nagabhushan N, Lee PH, Smith S. A Retrospective Cohort Study of the Utility of Ultrasound, 99mTc-Sestamibi Scintigraphy, and Four-Dimensional Computed Tomography for Pre-Operative Localization of Parathyroid Disease To Facilitate Minimally Invasive Parathyroidectomy. Cureus. 2022 Jan;14(1):e21177. doi: 10.7759/cureus.21177. eCollection 2022 Jan. PubMed PMID: 35165625; PubMed Central PMCID: PMC8837380.

Varghese J, Gohari S, Regrag F, Rizki H, Faheem M, Al Naqqash A, Johnson L, Ledwidge S, Hu J, Dickens R, Wilkinson M, Jones L, Suaris T. Breast Density Notification: Current UK National Practice. Clin Breast Cancer. 2022 Jan;22(1):e101-e107. doi: 10.1016/j.clbc.2021.04.013. Epub 2021 Jun 5. PubMed PMID: 34099394.

Varghese J, Gohari SS, Rizki H, Faheem M, Langridge B, Kümmel S, Johnson L, Schmid P. A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction. Breast. 2021 Feb;55:55-62. doi: 10.1016/j.breast.2020.11.023. Epub 2020 Dec 3. Review. PubMed PMID: 33341706; PubMed Central PMCID: PMC7750646.

Patel V, Rizki H, Varghese J. A mindful response to doctors' mental health. BMJ. 2020 Dec 1;371:m4687. doi: 10.1136/bmj.m4687. PubMed PMID: 33262110.

Potter S, Trickey A, Rattay T, O'Connell RL, Dave R, Baker E, Whisker L, Skillman J, Gardiner MD, Macmillan RD, Holcombe C. Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction. Br J Surg. 2020 Jun;107(7):832-844. doi: 10.1002/bjs.11468. Epub 2020 Feb 19. PubMed PMID: 32073654.

Hillyar C, Rizki H, Abbassi O, Miles-Dua S, Clayton G, Gandamihardja T, Smith S. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer. Cureus. 2020 Apr 6;12(4):e7552. doi: 10.7759/cureus.7552. PubMed PMID: 32382456; PubMed Central PMCID: PMC7202586.

Rizki H, Hillyar C, Abbassi O, Miles-Dua S. The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer. Cureus. 2020 Mar 14;12(3):e7269. doi: 10.7759/cureus.7269. PubMed PMID: 32195072; PubMed Central PMCID: PMC7075474.

O'Connell RL, Rattay T, Dave RV, Trickey A, Skillman J, Barnes NLP, Gardiner M, Harnett A, Potter S, Holcombe C. The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study. Br J Cancer. 2019 Apr;120(9):883-895. doi: 10.1038/s41416-019-0438-1. Epub 2019 Mar 29. PubMed PMID: 30923359; PubMed Central PMCID: PMC6734656.


Private practice

Visit the Imperial College Healthcare Private care website